Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$91.22
$93.96
$79.52
$124.00
$23.07B1.331.02 million shs873,543 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$38.85
$31.47
$14.32
$39.28
$7.98B0.761.69 million shs3.72 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$67.27
$51.52
$22.28
$69.29
$26.69B1.058.01 million shs14.44 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$53.01
$47.81
$29.43
$90.32
$2.76B-2.221.75 million shsN/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+0.36%-4.93%+7.00%-14.52%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%+9.93%+16.67%+64.97%+141.30%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.18%+42.55%+39.48%+147.68%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%0.00%0.00%+74.15%-36.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$91.22
$93.96
$79.52
$124.00
$23.07B1.331.02 million shs873,543 shs
Immunovant, Inc. stock logo
IMVT
Immunovant
$38.85
$31.47
$14.32
$39.28
$7.98B0.761.69 million shs3.72 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$67.27
$51.52
$22.28
$69.29
$26.69B1.058.01 million shs14.44 million shs
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$53.01
$47.81
$29.43
$90.32
$2.76B-2.221.75 million shsN/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+0.36%-4.93%+7.00%-14.52%
Immunovant, Inc. stock logo
IMVT
Immunovant
0.00%+9.93%+16.67%+64.97%+141.30%
Moderna, Inc. stock logo
MRNA
Moderna
0.00%+5.18%+42.55%+39.48%+147.68%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.00%0.00%0.00%+74.15%-36.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.74
Moderate Buy$129.5642.03% Upside
Immunovant, Inc. stock logo
IMVT
Immunovant
2.45
Hold$37.33-3.90% Downside
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$37.13-44.80% Downside
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
2.08
Hold$76.6744.63% Upside

Current Analyst Ratings Breakdown

Latest IMVT, SLNO, MRNA, and BNTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$69.00 ➝ $77.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
6/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$32.00 ➝ $34.00
6/5/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Reiterated RatingMarket Perform
6/1/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Reiterated RatingBuy
5/27/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
UpgradeNeutralBuy$117.00 ➝ $135.00
5/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingNeutral
5/26/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetBuy$44.00 ➝ $62.00
5/22/2026
Immunovant, Inc. stock logo
IMVT
Immunovant
Boost Price TargetHold$23.00 ➝ $30.00
5/21/2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
Initiated CoverageMarket Perform$96.00
(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.11$1.34 per share68.32$96.59 per share0.94
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/A$4.19 per shareN/A
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B13.73N/AN/A$22.14 per share3.04
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$285.01M9.69$0.43 per share124.10$9.51 per share5.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)
Immunovant, Inc. stock logo
IMVT
Immunovant
-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
$20.89M$1.7729.959.89N/A33.70%22.85%18.25%8/5/2026 (Estimated)

Latest IMVT, SLNO, MRNA, and BNTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/20/2026Q4 2026
Immunovant, Inc. stock logo
IMVT
Immunovant
-$0.60-$0.73-$0.13-$0.73N/AN/A
5/4/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Immunovant, Inc. stock logo
IMVT
Immunovant
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
8.74
Immunovant, Inc. stock logo
IMVT
Immunovant
N/A
9.09
9.09
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
0.10
5.62
5.32

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Immunovant, Inc. stock logo
IMVT
Immunovant
47.08%
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
97.42%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Immunovant, Inc. stock logo
IMVT
Immunovant
1.80%
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
6.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Immunovant, Inc. stock logo
IMVT
Immunovant
120205.31 million201.61 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Soleno Therapeutics, Inc. stock logo
SLNO
Soleno Therapeutics
3052.12 million48.78 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioNTech stock logo

BioNTech NASDAQ:BNTX

$91.22 0.00 (0.00%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$90.75 -0.47 (-0.51%)
As of 06/26/2026 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Immunovant stock logo

Immunovant NASDAQ:IMVT

$38.85 0.00 (0.00%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$38.63 -0.22 (-0.57%)
As of 06/26/2026 07:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Moderna stock logo

Moderna NASDAQ:MRNA

$67.27 0.00 (0.00%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$67.14 -0.13 (-0.20%)
As of 06/26/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Soleno Therapeutics stock logo

Soleno Therapeutics NASDAQ:SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.